ABBOTT BIAXIN FOR MAC THERAPY HAS $1,800 ANNUAL COST
Executive Summary
ABBOTT BIAXIN FOR MAC THERAPY HAS $1,800 ANNUAL COST at the wholesale price level, the company estimates. FDA's Dec. 23 approval of the new indication for clarithromycin -- the "primary agent for the treatment of disseminated infection due to Mycobacterium avium complex" -- makes Biaxin the first drug to be approved for treating the AIDS-related infection.